Kura Oncology (KURA) Cash & Equivalents (2010 - 2026)

Kura Oncology (KURA) has 17 years of Cash & Equivalents data on file, last reported at $39.1 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 23.77% year-over-year to $39.1 million in Q1 2026; TTM through Mar 2026 was $39.1 million, a 23.77% decrease from a year earlier, with the FY2025 full-year figure at $149.1 million, down 33.57% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $39.1 million, down from $149.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for KURA reached as high as $224.5 million in Q4 2024 and fell as low as $27.1 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $66.8 million across 5 years, with a median of $49.1 million in 2023.
• Across the five-year window, Cash & Equivalents plunged 69.48% in 2022 and surged 501.48% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $51.8 million in 2022, then slipped by 27.96% to $37.3 million in 2023, then jumped by 501.48% to $224.5 million in 2024, then plunged by 33.57% to $149.1 million in 2025, then sank by 73.79% to $39.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $39.1 million in Q1 2026, $149.1 million in Q4 2025, and $95.3 million in Q3 2025.